reuptake in Medical Technology

XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain

... of Bicifadine -- a serotonin and norepinephrine reuptake inhibitor (SNRI) -- for the treatment of diabetic ... Importantly, Bicifadine has a unique ratio of reuptake inhibition of serotonin versus norepinephrine, ... Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic ...

Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting

... and body weight affect the rate of dopamine reuptake by inhibiting the dopamine transporter (DAT), ... designed. The effects of MSI-1436 on dopamine reuptake were investigated using in vivo fast-scan cyclic ... minutes and the resultant dopamine and rate of reuptake were measured. Peak concentrations of dopamine ...

DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947

... Phase Ib results for DOV 21,947, its lead triple reuptake inhibitor ("TRIP") for the treatment of ... underscore the therapeutic versatility of triple reuptake inhibitors such as DOV 21,947," said Dr. Phil ... of 2008. DOV 21,947 is a TRIP that inhibits the reuptake of the neurotransmitters serotonin, ...

FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain

... of action, combining mu-opioid receptor agonism and norepinephrine reuptake inhibition. Tapentadol tablets have been approved in 50 mg, 75 ... at parts of the brain that control how pain is perceived. Norepinephrine reuptake inhibitors are a type of central nervous system medication that increases ...

Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile

... of action, combining mu-opioid receptor agonism and norepinephrine reuptake inhibition in a single molecule. It is being developed in ... at parts of the brain that control how pain is perceived. Norepinephrine reuptake inhibitors are a type of central nervous system medication that increases ...

AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines

... in the treatment of GAD. Treatment typically includes selective- serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs); however, approximately 30 percent of patients do not ...

FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder

... of a class of drugs commonly referred to as serotonin and norepinephrine reuptake inhibitors (SNRI), has been studied in more than 27,000 patients ... pain. Based on pre-clinical studies, duloxetine is a balanced and potent reuptake inhibitor of serotonin and norepinephrine that is believed to potentiate ...

Popular Breast Cancer Drug Used with Certain Antidepressants Puts New Jersey Women at Risk

... of Medicine released a study revealing that women using tamoxifen to prevent a recurrence of breast cancer who also use certain selective serotonin reuptake inhibitors (SSRI), for example Prozac(R) (fluoxetine), Paxil(R) (paroxetine) and Zoloft(R) (sertraline), have up to twice the chance of having a ...

New Study: Antidepressants Commonly Prescribed with Tamoxifen Put Women at Much Higher Risk for Recurrent Breast Cancer

... drugs impact breast cancer recurrence rates when taken with tamoxifen. The antidepressants at issue are three widely used selective serotonin reuptake inhibitors (SSRIs), Prozac(R) (fluoxetine), Paxil(R) (paroxetine) and Zoloft(R) (sertraline), and are among a group of drugs known as CYP2D6 ...

March 2009 Mayo Clinic Health Letter Highlights Knee Repair Surgery, Anxiety Disorder and Preventing Blood Clots

... Medications, both antidepressants and anti-anxiety drugs, also can help. Among antidepressants, the first choice often is a selective serotonin reuptake inhibitor (SSRI). This category includes fluoxetine (Prozac), paroxetine (Paxil), sertraline (Zoloft) and citalopram (Celexa). Other antidepressants ...

Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia

... At the highest dose tested (10 mg) we expect to have full occupancy of 5HT2A receptors while adding incremental amounts of D2 receptor and serotonin reuptake transporter (SERT) occupancy. This has been confirmed in an ongoing human Positron Emission Tomography (PET) study where we have demonstrated that ...

Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia

... which occurred at a rate of less than 2%. About Milnacipran Milnacipran is a dual-reuptake inhibitor that preferentially blocks the reuptake of norepinephrine with higher potency than serotonin, two neurotransmitters thought to play a central role in the symptoms of fibromyalgia. ...

American Heart Association Scientific Statement: Heart Patients Should Be Screened, Treated for Depression

... therapy, physical activity, cardiac rehabilitation, antidepressant drugs or combinations of those treatments. -- Selective serotonin reuptake inhibitor (SSRI) treatment soon after a heart attack is considered safe, relatively inexpensive and may be effective for treating ...

MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product Development

... products, today announced the completion of pilot product development for its thin film formulation of escitalopram oxalate, a selective serotonin reuptake inhibitor. Escitalopram oxalate is indicated for depression and generalized anxiety disorders and is marketed under the brand name Lexapro(R). ...

European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder

... for those suffering from this debilitating condition." Duloxetine, a member of a class of drugs commonly referred to as serotonin and noradrenaline reuptake inhibitors,(13) is already approved to treat major depressive disorder and diabetic peripheral neuropathic pain. Duloxetine gained marketing ...

Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder

... and total sleep time over 8 weeks in patients with co-morbid insomnia and major depressive disorder (MDD) who were administered a Selective Serotonin reuptake Inhibitor (SSRI) for depression. Ambien CR also improved sleep-related next-day functioning measures. This data was presented at the SLEEP 2008 22nd ...

New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR

... centrally acting oral analgesic. It has a unique profile with two mechanisms of action, combining mu-opioid receptor agonism and norepinephrine reuptake inhibition in a single molecule. It is being developed in immediate-release formulation for acute pain and extended-release formulation for chronic ...

New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery

... pain treatment option." Tapentadol has a unique profile with two mechanisms of action, combining mu-opioid receptor agonism and norepinephrine reuptake inhibition in a single molecule. It is being developed in immediate-release formulation for acute pain and extended-release formulation for ...

Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents

... of tricyclic antidepressants (TCAs) with Lexapro. SSRIs and SNRIs (including Lexapro) and other psychotropic drugs that interfere with serotonin reuptake may increase the risk of bleeding events. Concomitant use of aspirin, NSAIDs, warfarin and other anticoagulants may add to the risk. Patients should ...

Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine

... including treatment with Treximet, particularly during combined use with selective serotonin reuptake inhibitors (SSRIs) or selective norepinephrine reuptake inhibitors (SNRIs). NSAID-containing products, including Treximet, should be prescribed with extreme caution in those with a prior history of ulcer ...

Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders

... therapies. Behaviorally, ITI-007 inhibited serotonin induced head twitches. Additionally, ITI-007 was shown to have an affinity for the serotonin reuptake site, an activity that potentially may be beneficial in treating affective disorders. ITI's CNSProfile(TM) has shown that, unlike some ...

Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results

... formulation that allows for the necessary preclinical work to be completed by the third quarter of 2008. Selective Norepinephrine reuptake Inhibitor (sNRI) for Neuropathic Pain -- Neurocrine completed a Phase I clinical trial with sNRI for neuropathic pain. The single ascending ...

Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs

... were consistent with a partial dopamine agonist profile. The Company's presentation demonstrated ITI-007 also has an affinity for the serotonin reuptake site, an activity that potentially may be beneficial in treating affective disorders. ITI's CNSProfile(TM) has shown, unlike some atypical ...

XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis

... in the development of therapeutics for the treatment of neuropathic pain and HCV. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain, which is currently in a Phase 2b study. XTL is also developing novel pre-clinical HCV ...

Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show

... or http://www.frx.com . About Milnacipran Milnacipran is a unique dual-reuptake inhibitor, which preferentially blocks the reuptake of norepinephrine with higher potency than serotonin, two neurotransmitters known to play an essential role in regulating pain and mood. It has been ...

DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study

... study to be available at the end of 2008. About DOV 21,947 Clinical research indicates that co-administrating drugs that, in combination, inhibit reuptake of the three neurotransmitters most closely linked to depression - serotonin, norepinephrine and dopamine - can produce greater overall efficacy than ...

In New Study, Duloxetine Reduced Non-specific Pain and Emotional Symptoms Associated with Depression

... of a class of drugs commonly referred to as serotonin and norepinephrine reuptake inhibitors (SNRIs), is approved in more than 70 countries for the ... cord. Based on pre-clinical studies, duloxetine is a balanced and potent reuptake inhibitor of serotonin and norepinephrine/noradrenaline. While the ...

Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome

... is the first of a new class of agents known as norepinephrine serotonin reuptake inhibitors, or NSRIs, which exerts its effect by preferentially inhibiting the reuptake of norepinephrine over serotonin, two neurotransmitters known to play an ...

In New Study, Duloxetine Was Equally Effective, Regardless of Switch Method, in Reducing Painful Symptoms in Ssri Non- or Partial-responders with Depression

... of a class of drugs commonly referred to as serotonin and norepinephrine reuptake inhibitors (SNRI) 5 , is approved in more than 70 countries for ... cord. Based on pre-clinical studies, duloxetine is a balanced and potent reuptake inhibitor of serotonin and norepinephrine/noradrenaline. Scientists ...

Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study

... The study directly compared Cipralex® (an allosteric serotonin reuptake inhibitor - ASRI) to duloxetine (a serotonin and noradrenaline reuptake inhibitor - SNRI) and also demonstrated that Cipralex® was better ...

Stanford Study Finds No Conclusive Benefit From Treating Kleptomania With Medication

... The medication in the trial was escitalopram, marketed as Lexapro. The drug belongs to a class of antidepressants known as selective serotonin reuptake inhibitors, and earlier studies have suggested that SSRIs can be effective in treating some impulse control disorders, such as skin picking. In an ...

Data Suggest Cymbalta Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain

... to both help regulate the perception of pain and mediate core mood symptoms. Based on pre-clinical studies, duloxetine is a balanced and potent reuptake inhibitor of serotonin and norepinephrine that is believed to potentiate the activity of these chemicals in the central nervous system (brain and ...

Wyeth Presents Phase 3 Data for Pristiq, an Investigational Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats

... sexual adverse events, and there was no statistical difference between Pristiq and placebo. About Pristiq Pristiq is a serotonin-norepinephrine reuptake inhibitor (SNRI) being studied by Wyeth as a potential treatment for multiple indications, including moderate-to-severe menopausal hot flashes and ...

Data Suggest Cymbalta Improved Functioning in Patients with Generalized Anxiety Disorder

... to both mediate core mood symptoms and help regulate the perception of pain. Based on pre-clinical studies, duloxetine is a balanced and potent reuptake inhibitor of serotonin and norepinephrine that is believed to potentiate the activity of these chemicals in the central nervous system (brain and ...

Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo

... or losses were not observed in patients administered desvenlafaxine succinate. About Desvenlafaxine Desvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) studied as a potential treatment for adult men and women with MDD. Wyeth submitted a New Drug Application (NDA) for MDD on December ...

New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder

... somnolence, sweating, anorexia (loss of appetite), tremor and impotence. About Desvenlafaxine Desvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) studied as a potential treatment for adult men and women with MDD. Wyeth submitted a New Drug Application (NDA) for MDD on December ...

Blood Levels of Paliperidone Extended-Release Tablets are Not Increased by Common Antidepressant

... to new data presented today at the 160th Annual Meeting of the American Psychiatric Association. Paroxetine, a selective serotonin reuptake inhibitor (SSRI), is an antidepressant known to interact with several antipsychotic medications. This new study showed there was no clinically ...

Study Suggests Strattera Improved ADHD Symptoms in Patients With Comorbid Alcohol Abuse

... for choosing appropriate treatment and monitoring for both safety and efficacy.(3,4,5) About Strattera Strattera, a selective norepinephrine reuptake inhibitor, is the first FDA-approved non-stimulant to treat ADHD in children, adolescents and adults. Since its first approval in the United States ...

Antidepressant Use May Boost Fracture Risk, From Harvard Women's Health Watch

... of Harvard Women's Health Watch. A recent study found that people ages 50 and over who regularly took antidepressants called selective serotonin reuptake inhibitors (SSRIs) had double the rate of fractures as people not using such medications. Other research points to depression itself as a source of ...